Opportunities and challenges of immunotherapy for dMMR/ MSI-H colorectal cancer

被引：0
|
作者：
Zhang, Qi [1 ]
Li, Jian [2 ]
Shen, Lin [2 ]
Li, Yongsheng [1 ]
Wang, Xicheng [2 ]
机构：
[1] Chongqing Univ, Canc Hosp, Dept Med Oncol, Chongqing 400030, Peoples R China
[2] Peking Univ, Beijing Canc Hosp & Inst, Dept Gastrointestinal Oncol, Lab Carcinogenesis & Translat Res,Sch Oncol,Minist, Beijing 100142, Peoples R China
来源：
CANCER BIOLOGY & MEDICINE | 2023年 / 20卷 / 10期
关键词：
MISMATCH REPAIR DEFICIENCY; RECTAL-CANCER; MICROENVIRONMENT; BLOCKADE;
D O I：
10.20892/j.issn.2095-3941.2023.0240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：706 / 712
页数：7
相关论文
共 50 条
  • [21] The clinical and genomic characteristics of MSI-h/dMMR lung cancer.
    Qin, Jianwen
    Shi, Dongsheng
    Yin, Yan
    Bin Liu
    Wang, Lei
    Sun, Tingting
    Zhang, Qin
    Qi, Chuang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response
    Fox, Daniel Aaron
    Konishi, Tsuyoshi
    Kaur, Harmeet
    You, Y. Nancy
    Raghav, Kanwal Pratap Singh
    Ge, Phillip S.
    Messick, Craig
    Johnson, Benny
    Morris, Van K.
    Thomas, Jane V.
    Shah, Preksha
    Bednarski, Brian K.
    Kopetz, Scott
    Chang, George J.
    Ludford, Kaysia
    Higbie, Victoria
    Overman, Michael J.
    Bhamidipati, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
    Yupeng Jiang
    Yuyao Liu
    Hong Huang
    Tiantian Zhao
    Zengyi Zhao
    Yawen Gao
    Cancer Immunology, Immunotherapy, 74 (3)
  • [24] MSI-H/dMMR mCRC: ICIs in the first line?
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 748 - 748
  • [25] MSI-H/dMMR mCRC: ICIs in the first line?
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 748 - 748
  • [26] Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.
    LaPelusa, Michael Brian
    San Lucas, Francis A.
    Iorgulescu, Bryan
    Patel, Keyur P.
    You, Nancy
    Foo, Wai Chin
    Maru, Dipen M.
    Kopetz, Scott
    Ludford, Kaysia
    Morris, Van K., II
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Fine-tuning immunotherapy in MMR-D/MSI-H colorectal cancer
    Sahin, Ibrahim Halil
    COLORECTAL CANCER, 2019, 8 (04)
  • [28] Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H diseaseColorectal cancer
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2025, 22 (2) : 79 - 79
  • [29] Neoadjuvant pembrolizumab for localized solid MSI-H/dMMR tumors
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (10):
  • [30] Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers
    Ajani, Jaffer A.
    Pedersen, Katrina S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
12345